NCT06723171

Evaluation of Safety and Efficacy of IRX4204 in Mild to Moderate Plaque Psoriasis

A 4-Week, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of the RXR Agonist Compound IRX4204 for the Treatment of Mild to Moderate Plaque Psoriasis

• Status: Suspended
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Io Therapeutics · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to learn if IRX4204 works to treat plaque psoriasis in adults. It will also learn about the safety of IRX4204. The main questions it aims to answer are: * Does IRX4204 treat plaque psoriasis symptoms? * Does IRX4204 treat plaque psoriasis symptoms better than someone who is not being treated? * What medical problems do participants have when taking IRX4204? Researchers will compare IRX4204 to a placebo (a look-alike substance that contains no drug) to see if the drug works to treat mild to moderate plaque psoriasis. Participants will: * Take IRX4204 every day for 28 days * Visit the clinic once every week for checkups and tests * Complete specific assessments about plaque psoriasis and changes to plaques

Conditions

• Psoriasis
• Plaque Type Psorisis
• Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	IRX4204	Active Treatment
OTHER	Placebo	Placebo

Timeline

• Start date: 2026-03-01
• Primary completion: 2026-03-01
• Completion: 2026-04-01
• First posted: 2024-12-09
• Last updated: 2026-03-03

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study